| Beberashvili, Ilia |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Recruiting | 2 | 50 | RoW | Colchicine 0.5 MG, Placebo | Assaf-Harofeh Medical Center | End Stage Renal Disease on Dialysis | 02/23 | 02/23 | | |
| Bocchi, Edimar |
| Active, not recruiting | 2 | 109 | Europe, Canada, US, RoW | CardiolRx, Cannabidiol | Cardiol Therapeutics Inc., Cardiol Therapeutics Inc. | Acute Myocarditis | 01/25 | 02/25 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Wang, Hao |
TNK-PLUS, NCT06221371: Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion |
|
|
| Recruiting | 3 | 390 | RoW | rhTNK-tPA, Tenecteplase, direct EVT | Beijing Tiantan Hospital, Linyi People's Hospital | Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment | 12/24 | 05/25 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT04892498: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) |
|
|
| Recruiting | 2 | 66 | RoW | Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF, IL-2 | Second Affiliated Hospital of Soochow University | Advanced Refractory Solid Tumors | 08/23 | 08/24 | | |
NCT03478358: Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | 177Lu-DOTA-EB-TATE 1, 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE 2, 177Lu-DOTA-EB-TATE 3, 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine), 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Peking Union Medical College Hospital | Neuroendocrine Tumors | 12/22 | 05/23 | | |
NCT04748068: Use of Glidesheath Slender to Reduce Radial Artery Occlusion Following 7 French Transradial Coronary Intervention |
|
|
| Not yet recruiting | N/A | 500 | RoW | 7-Fr Glidesheath Slender, Glidesheath Slender, Terumo, Tokyo, Japan, Cordis 7-Fr radial sheath | China National Center for Cardiovascular Diseases | Radial Artery Occlusion, Coronary Artery Disease | 05/21 | 05/21 | | |
| Recruiting | N/A | 3500 | RoW | | Tang-Du Hospital, Esaote (Shenzhen) Medical Equipment Co. Ltd, The First Affiliated Hospital, Zhejiang University School of Medicine, Shannxi Provincial People's Hospital, Shengjing Hospital, First Hospital of China Medical University, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Beijing University of Chinese Medicine Third Affiliated Hospital, The First Affiliated Hospital of Shanxi Medical University, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, The First Hospital of Jilin University, The Afffiliated Hospital of Guizhou Medical University, Yan An Hospital Affiliated to Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Third Xiangya Hospital of Central South University, Ruijin Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Anhui Medical University, The First Affiliated Hospital of USTC, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Xinjiang Medical University, Hospital of Northwestern Polytechnical University, GEM Flower Xian Changqing Staff Hospital, Xi'an Central Hospital, The Second Affiliated Hospital of Xi'an Medical University, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Karamay Central Hospital of Xinjiang, The Fourth Affiliated Hospital of Xinjiang Medical University, Xi'an No.1 Hospital, Xianyang Hospital of Yan'an University, General Hospital of Xinjiang Production and Construction Corps, Air Force Medical Center | Healthy, Adults, Carotid Intima-media Thickness, Vascular Stiffness, Chinese | 05/22 | 05/22 | | |
NCT06014476: Psychological Symptoms and Burden in Caregivers of Patients With Disorders of Consciousness |
|
|
| Completed | N/A | 256 | RoW | questionnaires, Coma Recovery Scale-Revised (CRS-R) | Hangzhou Normal University | Psychological Distress, Anxiety Depression, Burden, Caregiver, Disorders of Consciousness | 10/22 | 10/22 | | |
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study) |
|
|
| Active, not recruiting | N/A | 88 | RoW | WeFlow-Arch Modeler Embedded Branch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 02/25 | 02/29 | | |
NCT06143540: Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | N/A | 30 | RoW | | Sichuan Provincial People's Hospital | Interstitial Lung Disease | 05/24 | 07/24 | | |
NCT05944198: Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis |
|
|
| Completed | N/A | 40 | RoW | | Sichuan Provincial People's Hospital | Rheumatoid Arthritis | 02/24 | 02/24 | | |
| Not yet recruiting | N/A | 142 | NA | Deep Hyperthermia | Peking University Third Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital | Hyperthermia, Radiotherapy | 12/23 | 12/24 | | |
NCT05976620: Clinical Study of 18F-FAPI-RGD in Breast Tumors |
|
|
| Completed | N/A | 30 | RoW | | Sichuan Provincial People's Hospital | Breast Tumors | 12/23 | 02/24 | | |
| Completed | N/A | 30 | RoW | | Sichuan Provincial People's Hospital | Renal Tumor | 01/24 | 02/24 | | |
COSTAR, NCT06583070: SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer |
|
|
| Recruiting | N/A | 300 | RoW | Radiation therapy | Peking University First Hospital, Peking University Third Hospital | Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer | 03/27 | 03/27 | | |
MATESHIP, NCT05290454: mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients |
|
|
| Recruiting | N/A | 342 | RoW | mNGS-guided treatment | Qilu Hospital of Shandong University, Jinan Central Hospital | Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia, Infections | 06/24 | 09/24 | | |
| Recruiting | N/A | 100 | RoW | | Sichuan Provincial People's Hospital | Neoplasms | 09/24 | 10/24 | | |
| Recruiting | N/A | 30 | RoW | | Sichuan Provincial People's Hospital | Urothelial Carcinoma | 09/24 | 10/24 | | |
| Not yet recruiting | N/A | 550 | RoW | lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Colorectal Neoplasms, Fluorescence, Lymph Node Excision | 12/26 | 06/27 | | |
ENDURE-APAC, NCT05578300: Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific |
|
|
| Recruiting | N/A | 350 | RoW | Thrombus analyses, Imaging assessment | Chinese University of Hong Kong, Linyi People's Hospital | Ischemic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases, Major Adverse Cardiovascular Event | 10/32 | 12/32 | | |
| Recruiting | N/A | 100000 | RoW | Multi-disciplinary assessment | Beijing Tiantan Hospital | Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure, Aortic Diseases, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Cerebral Infarction, Occlusion and Stenosis of Precerebral Arteries, Occlusion and Stenosis of Cerebellar Arteries, Cerebral Aneurysm, Moyamoya Disease, Arteriovenous Malformation of Cerebral Vessels | 12/32 | 12/32 | | |
NCT05348902: Locked-in Syndrome Caused by Pulmonary Arteriovenous Malformation: A Case Report |
|
|
| Recruiting | N/A | 1 | RoW | In this study, only cases were collected and reported without any intervention or adverse reactions | Second Affiliated Hospital, School of Medicine, Zhejiang University | Locked-In Syndrome；Pulmonary Arteriovenous Malformation | 06/22 | 06/22 | | |
| Ren, Yu |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
NCT06593132: Single Port Endoscopic Breast Conserving Surgery |
|
|
| Recruiting | N/A | 200 | RoW | endoscopic breast conserving surgery | Ren,Yu | Breast Conserving Surgery, Endoscopic Surgery | 12/24 | 06/25 | | |
| Wu, Jiong |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 406 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NeoTENNIS, NCT04418154: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 70 | RoW | epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel, Toripalimab | Fudan University | Triple Negative Breast Cancer | 09/22 | 12/25 | | |
NCT04881929: Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | KN026, Docetaxel | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 11/22 | 02/23 | | |
NCT06178159: DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Disitamab Vedotin Injection, DV,RC48-ADC, Pertuzumab Injection, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 12/24 | 06/25 | | |
NCT06389006: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 79 | RoW | Disitamab Vedotin for Injection, RC48, Toripalimab, JS001, Epirubicin, Cyclophosphamide, CTX | RemeGen Co., Ltd. | Breast Cancer | 06/25 | 12/26 | | |
NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
NCT06555068: A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients |
|
|
| Recruiting | 1/2 | 528 | RoW | HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole, HRS-6209 in Combination with HRS-8080 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Unresectable or Metastatic Breast Cancer | 12/25 | 08/26 | | |
NCT05805956: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 |
|
|
| Recruiting | 1/2 | 105 | RoW | IMM2902 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma | 10/24 | 10/24 | | |
| Recruiting | 1/2 | 60 | RoW | PM8002, nab-paclitaxel | Biotheus Inc. | TNBC | 10/26 | 10/26 | | |
NCT05203601: A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. |
|
|
| Completed | 1 | 36 | RoW | SIBP-03 | Shanghai Institute Of Biological Products, Fudan University | Tumor | 12/22 | 12/22 | | |
| Completed | 1 | 49 | RoW | AK117 | Akeso | Neoplasms Malignant | 01/22 | 05/23 | | |
| Completed | 1 | 28 | RoW | AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus | AstraZeneca | ER+, HER2-, Metastatic Breast Cancer | 09/23 | 09/23 | | |
| Recruiting | 1 | 177 | RoW | HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
BL-B01D1-104, NCT05470348: A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 06/25 | 12/25 | | |
BL-B16D1-103, NCT06493864: A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 07/26 | 07/26 | | |
NCT04993430: A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer |
|
|
| Recruiting | 1 | 90 | RoW | HRS8807, HRS8807、SHR6390 | Shanghai Hengrui Pharmaceutical Co., Ltd. | ER-Positive, HER2-Negative Breast Cancer | 12/24 | 12/24 | | |
NCT05293964: Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 1 | 214 | RoW | SIM0270, SCR6852, Palbociclib, everolimus | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 09/25 | | |
NCT06591039: A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China |
|
|
| Recruiting | N/A | 20000 | RoW | The study did not involve intervention in the patient's treatment regimen | Fudan University | Breast Neoplasms | 07/25 | 12/25 | | |
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA) |
|
|
| Active, not recruiting | N/A | 440 | RoW | Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra | Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 04/23 | 09/24 | | |
| Recruiting | N/A | 10000 | RoW | breast reconstruction, oncoplastic breast-conserving surgery | Fudan University, First Affiliated Hospital of Chongqing Medical University, Tianjin Medical University Cancer Institute and Hospital, First Hospital of China Medical University, Guangdong Provincial People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Xijing Hospital, Air Force Medical University, Hunan Province Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Xinjiang Medical University, Hubei Cancer Hospital, The Affiliated Hospital of Qingdao University, First People's Hospital of Hangzhou | Patient Reported Outcome Measures, Breast Reconstruction, Oncoplastic Breast-conserving Surgery, Breast Cancer | 12/24 | 12/24 | | |
PHC-BC, NCT04281641: Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer |
|
|
| Recruiting | N/A | 94 | RoW | TCHP | Fudan University | HER2-positive Breast Cancer | 04/25 | 04/30 | | |
CAPPELLA, NCT05512286: Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction |
|
|
| Recruiting | N/A | 80 | RoW | Preoperative radiotherapy, Postmastectomy radiotherapy | Fudan University, Huashan Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Yunnan Cancer Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital | Breast Cancer | 07/26 | 10/27 | | |
| Shirin, Haim |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
NCT06566872: Collecting Recorded Videos of Colonoscopy and Gastroscopy Tests for the Evaluation of the (ME-APDS). |
|
|
| Recruiting | N/A | 700 | RoW | ME-APDS, Automatic Polyp Detection System (ME-APDS) Medical Device | Magentiq Eye LTD | Colon Polyp | 12/25 | 12/25 | | |
NCT05400408: Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study |
|
|
| Not yet recruiting | N/A | 250 | RoW | VOX | Scentech Medical Technologies Ltd | Colorectal Cancer, Pancreatic Cancer | 01/25 | 03/25 | | |
| cekin, ayhan hilmi |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06521879: Probiotic Use in Oral Iron Replacement Deficiency Anemia Patients Initiating Oral Iron Replacement |
|
|
| Completed | N/A | 295 | RoW | Lactobacillus plantarum 299v probiotic support | Antalya Training and Research Hospital | Iron Deficiency Anemia Treatment, Iron Deficiency Anemia | 07/23 | 07/23 | | |
| Gebara, Otavio |
| Completed | 3 | 507 | RoW | Dapagliflozin 10mg Tab, Farxiga, Standard of Care | Hospital Israelita Albert Einstein | Critical Illness, Sepsis | 10/23 | 10/23 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Oliinyk, Oleksandr |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Gingras, Isabelle |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Poplyonkin, Yevgen |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Leibowitz-Amit, Raya |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
| Merose, Rotem |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05382520: Sensory Rehabilitation in Chemotherapy Induced Peripheral Neuropathy (CIPN) |
|
|
| Recruiting | N/A | 12 | RoW | Questionares and practice | Assaf-Harofeh Medical Center, Zefat Academic College | CIPN | 01/24 | 12/25 | | |
| Xu, Jingwei |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 05/25 | 05/25 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
| Saporito, Wladimir Faustino |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
|
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Leibowitz, Raya |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
| niu, zhaofeng |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
